A Reversal for Aslan Pharmaceuticals Limited – American Depositar (NASDAQ:ASLN) Is Near. The Stock Has Decrease in Shorts

September 16, 2018 - By Jack Shaw

The stock of Aslan Pharmaceuticals Limited – American Depositar (NASDAQ:ASLN) registered a decrease of 90% in short interest. ASLN’s total short interest was 200 shares in September as published by FINRA. Its down 90% from 2,000 shares, reported previously.

The stock decreased 1.79% or $0.14 during the last trading session, reaching $7.66. About 1,193 shares traded. ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) has 0.00% since September 16, 2017 and is . It has underperformed by 15.62% the S&P500.

ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, develops therapeutics for the treatment cancer in Asia, the United States, Europe, and internationally. The company has market cap of $206.56 million. The company's product pipeline includes Varlitinib, a novel agent, which has completed Phase II studies in gastric and breast cancer, and entered into pivotal studies for biliary tract cancer; ASLAN002, a potent cMET and Recepteur d'Origine Nantais inhibitor that is in Phase II development for the treatment of gastric and breast cancer; and ASLAN003, a novel DHODH inhibitor, which is in Phase I clinical trials to treat acute myeloid leukemia and solid tumors. It currently has negative earnings. It is also developing ASLAN004, a monoclonal IL4/IL13 antibody that is under preclinical development for asthma and other tumor types; and ASLAN005, a monoclonal antibody, which is under preclinical development for RON, an immune checkpoint inhibitor.

More news for ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) were recently published by: Nasdaq.com, which released: “ASLAN Pharmaceuticals to Present at HC Wainwright 20th Annual Global Investment Conference” on September 04, 2018. Nasdaq.com‘s article titled: “ASLAN Pharmaceuticals Granted Orphan Drug Designation by the FDA for ASLAN003 for the Treatment of Acute …” and published on August 20, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.